Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wood, E. Articles by Hogg, R. S. Search for Related Content PubMed PubMed Citation Articles by Wood, E. Articles by Hogg, R. S. Related Collections Other public health Drugs: immunological products and vaccines HIV infection, AIDS

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users

Evan Wood^*, Julio S.G. Montaner^*, Benita Yip^*, Mark W. Tyndall^*, Martin T. Schechter^*, Michael V. O'Shaughnessy^* and Robert S. Hogg^*

*British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC; Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; Department of Medicine, University of British Columbia, Vancouver, BC.

Correspondence to: Dr. Evan Wood, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard St., Vancouver BC V6Z 1Y6; fax 604 806-9044; ewood{at}hivnet.ubc.ca

Background: The benefits of highly active antiretroviral therapy (HAART) for the treatment of HIV infection are well documented, but concerns regarding access and adherence to HAART are growing. We evaluated virological responses to HAART among HIV-1 infected patients who were injection drug users (IDUs) in a population-based setting where HIV/AIDS care is delivered free of charge.

Methods: We evaluated previously untreated HIV-1 infected men and women who initiated HAART between Aug. 1, 1996, and July 31, 2000, and who were followed until Mar. 31, 2002, in a province-wide HIV treatment program. We used Kaplan–Meier methods and Cox proportional hazards regression in our evaluation of time to suppression (i.e., less than 500 copies/mL) and rebound (i.e., 500 copies/mL or more) of plasma HIV-1 RNA, with patients stratified according to whether or not they had a history of injection drug use.

Results: Overall, 1422 patients initiated HAART during the study period, of whom 359 (25.2%) were IDUs. In Kaplan–Meier analyses, the cumulative suppression rate at 12 months after initiation of HAART was 70.8% for non-IDUs and 51.4% for IDUs (p < 0.001) (these values include people who achieved suppression before 12 months but who might not have been followed for the full 12-month period). Among patients who achieved suppression of plasma HIV-1 RNA, the cumulative rebound rate at 12 months after initial suppression was 23.8% for non-IDUs and 34.7% for IDUs (p < 0.001). However, after adjustment for adherence and other covariates, the rates of HIV-1 RNA suppression (adjusted relative hazard 0.9, 95% confidence interval [CI] 0.7–1.0) and HIV-1 RNA rebound (adjusted relative hazard 1.3, 95% CI 1.0–1.6) were similar between non-IDUs and IDUs. Differences between non-IDUs and IDUs were even less pronounced in subanalyses that considered only therapy-adherent patients (p > 0.1).

Interpretation: Non-IDUs and IDUs had similar rates of HIV-1 RNA suppression and rebound after the initiation of HAART, once lower levels of adherence were taken into account. Nevertheless, the lower virological response rates among IDUs suggest that, unless interventions are undertaken to improve adherence, these patients may experience elevated rates of disease progression and use of medical services in our setting.

This article has been cited by other articles:

				M R Jordan, H La, H D Nguyen, H Sheehan, T T M Lien, D V Duong, J Hellinger, C Wanke, and A M Tang Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam Int J STD AIDS, June 1, 2009; 20(6): 418 - 422. [Abstract] [Full Text] [PDF]

				T. Kerr, R. S. Hogg, B. Yip, M. W. Tyndall, J. Montaner, and E. Wood Validity of Self-Reported Adherence Among Injection Drug Users J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2008; 7(4): 157 - 159. [Abstract] [PDF]

				E. J. Mills, J. B. Nachega, I. Buchan, J. Orbinski, A. Attaran, S. Singh, B. Rachlis, P. Wu, C. Cooper, L. Thabane, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA, August 9, 2006; 296(6): 679 - 690. [Abstract] [Full Text] [PDF]

				K. Shannon, T. Kerr, C. Lai, T. Ishida, E. Wood, J. S. G. Montaner, R. S. Hogg, and M. W. Tyndall Nonadherence to Antiretroviral Therapy Among a Community With Endemic Rates of Injection Drug Use J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 66 - 72. [Abstract] [PDF]

				J. R. Arribas The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens J. Antimicrob. Chemother., September 1, 2004; 54(3): 587 - 592. [Abstract] [Full Text] [PDF]

				A. R. Templeton, R. A. Reichert, A. E. Weisstein, X.-F. Yu, and R. B. Markham Selection in Context: Patterns of Natural Selection in the Glycoprotein 120 Region of Human Immunodeficiency Virus 1 Within Infected Individuals Genetics, August 1, 2004; 167(4): 1547 - 1561. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2003, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.